🔎 Trials Near Me

Home › Autism › NCT05003960

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Autism

RecruitingPhase 1

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Autism

Who can join

All ages · All sexes

Full eligibility criteria
Inclusion Criteria:

* Diagnosis of Autism

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety
* Previous organ transplant
* Seizure disorder
* Hypersensitivity to sulfur

About the study

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Autism

What is being tested

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 15 · Started: Jan 23, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05003960

Locations in the U.S.

FloridaProdromos Stem Cell Institute, Naples

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.